Navigation Links
The MDS foundation supports vidaza's recommendation for European approval
Date:10/27/2008

The Myelodysplastic Syndromes (MDS) Foundation supports the positive opinion from the European Union's Committee for Medicinal Products for Human Use (CHMP) recommending approval of VIDAZA (azacitidine) for specific types of MDS patients, including those with high-risk MDS, chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).

The CHMP positive opinion was based upon data from the AZA-001 trial, which found that VIDAZA nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are very encouraged by the CHMP's recommendation for marketing approval for VIDAZA," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "The MDS Foundation is committed to making sure that patients in need are aware of and have access to new treatments, like VIDAZA, that can help patients to live longer and allow them to have a better quality of life."

The AZA-001 trial also showed that, VIDAZA delays the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells; red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


'/>"/>

Contact: Kathy Heptinstall
kheptinstall@MDS-Foundation.org
800-637-0839
The Myelodysplastic Syndromes Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. Meyskens honored with AACR-Prevent Cancer Foundation award
2. Parkinsons Disease Foundation announces award of $150,000
3. The Camille & Henry Dreyfus Foundation to host important symposium on chemistry and the environment
4. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
5. National Science Foundation grant expands UMCES oyster research
6. Dunn Foundation gives Rice $3M for collaborative research grants
7. National Science Foundation grants Clemson professors award to develop nanoprobes
8. Entertainment Software Association Foundation awards grant to FAS for immune attack
9. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
10. UT Knoxville wins 2 $3M National Science Foundation research and education grants
11. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2020)... ... July 21, 2020 , ... ... innovation in technology and compliance, announces a new solution to manage regulated workloads ... every layer of their technology stack complies with FDA and global regulations. USDM's ...
(Date:7/10/2020)... CHICAGO (PRWEB) , ... July 09, 2020 , ... Today ... Umami Advantage, which will share insight on the “fifth taste” phenomenon that is revolutionizing ... snacks. The Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in ... Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide ...
Breaking Biology News(10 mins):
(Date:8/7/2020)... THE WOODLANDS, Texas (PRWEB) , ... August 06, ... ... gene therapy and DNA vaccine industries, announces it has closed on the purchase ... Deison Technology Park in Conroe, TX and includes over 21 acres in the ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now offering ... 50 million stem cells total, patients may choose which extremities they would like treated. ... joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained from ...
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
(Date:7/31/2020)... ... 29, 2020 , ... The SDX® Respiratory Gating System ... has reached its 20th anniversary of worldwide use. Introduced in the US over ... including University of Pennsylvania, University of Michigan, University of Maryland, University of California ...
Breaking Biology Technology: